Search Results - María Buti

Refine Results
  1. 1
    Current therapies for chronic hepatitis B

    Current therapies for chronic hepatitis B by Maria Buti, MD

    Published 2003-07-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Management of direct antiviral agent failures

    Management of direct antiviral agent failures by María Buti, Rafael Esteban

    Published 2016-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Long-term outcome after interferon therapy in patients with chronic hepatitis C.

    Long-term outcome after interferon therapy in patients with chronic hepatitis C. by Maria Buti, Rafael Esteban

    Published 2007-10-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Tratamiento de hepatitis crónica por virus B

    Tratamiento de hepatitis crónica por virus B by María Buti, Rafael Esteban

    Published 2008-01-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Hepatitis E virus: new faces of an old infection

    Hepatitis E virus: new faces of an old infection by Mar Riveiro-Barciela, Francisco Rodríguez-Frías, María Buti

    Published 2013-11-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    A Case Report of Hepatocellular Carcinoma 5 Years After HBsAg Loss in Chronic Hepatitis Delta: How Long Surveillance is Required?

    A Case Report of Hepatocellular Carcinoma 5 Years After HBsAg Loss in Chronic Hepatitis Delta: How Long Surveillance is Required? by Laura Escolà-Vergé, Mar Riveiro-Barciela, Maria Buti

    Published 2017-07-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

    New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents by Josep Quer, Maria Buti, Maria Cubero, et al

    Published 2010-11-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B

    Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B by Luisa Roade, Mar Riveiro-Barciela, Rafael Esteban, Maria Buti

    Published 2021-02-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B

    Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B by Itziar Oyagüez, María Buti, Max Brosa, Magdalena Rueda, Miguel A. Casado

    Published 2017-05-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Healthcare value of implementing hepatitis C screening in the adult general population in Spain.

    Healthcare value of implementing hepatitis C screening in the adult general population in Spain. by María Buti, Raquel Domínguez-Hernández, Miguel Ángel Casado, Eliazar Sabater, Rafael Esteban

    Published 2018-01-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Cost-effectiveness of a hepatitis B virus screening strategy to prevent reactivation in patients with hematologic neoplasms

    Cost-effectiveness of a hepatitis B virus screening strategy to prevent reactivation in patients with hematologic neoplasms by Javier Crespo, Rafael Esteban, Covadonga Torres, Itziar Oyagüez, Miguel Ángel Casado, María Buti

    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    Hepatitis E Virus Epidemiology in Industrialized Countries

    Hepatitis E Virus Epidemiology in Industrialized Countries by Pilar Clemente-Casares, Sonia Pina, Maria Buti, Rosend Jardi, Margarita Martín, Sílvia Bofill-Mas, Rosina Girones

    Published 2003-04-01
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey

    Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey by Loreta A. Kondili, Maria Buti, Mar Riveiro-Barciela, Mojca Maticic, Francesco Negro, Thomas Berg, Antonio Craxì

    Published 2022-09-01
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening Rate

    The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening Rate by Laia Aceituno, Juan Bañares, Lourdes Ruiz-Ortega, Ana Callejo-Pérez, Eva Muñoz-Couselo, Carolina Ortiz-Velez, Nely Díaz-Mejía, Ana Barreira-Díaz, María José Carreras, Anna Farriols, María Buti, María Buti, Mar Riveiro-Barciela, Mar Riveiro-Barciela

    Published 2022-07-01
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    Corrigendum to ‘Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B’ [JHEP Reports 3 (2021)]

    Corrigendum to ‘Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B’ [JHEP Reports 3 (2021)] by Maria Buti, Maria Stepanova, Adriana Palom, Mar Riveiro-Barciela, Fatema Nader, Luisa Roade, Rafael Esteban, Zobair Younossi

    Published 2022-09-01
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B

    Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B by Maria Buti, Maria Stepanova, Adriana Palom, Mar Riveiro-Barciela, Fatema Nader, Luisa Roade, Rafael Esteban, Zobair Younossi

    Published 2021-06-01
    Get full text
    Article
    Save to List
    Saved in:
  17. 17
    Hepatitis B e antigen status and hepatitis B DNA levels in women of childbearing age with chronic hepatitis B infection screening for clinical trials.

    Hepatitis B e antigen status and hepatitis B DNA levels in women of childbearing age with chronic hepatitis B infection screening for clinical trials. by Tram T Tran, Stuart C Gordon, Scott Fung, Phillip Dinh, Leland Yee, Eduardo Bruno Martins, Maria Buti, Patrick Marcellin

    Published 2015-01-01
    Get full text
    Article
    Save to List
    Saved in:
  18. 18
    Clinical application of estimating hepatitis B virus quasispecies complexity by massive sequencing: correlation between natural evolution and on-treatment evolution.

    Clinical application of estimating hepatitis B virus quasispecies complexity by massive sequencing: correlation between natural evolution and on-treatment evolution. by Maria Homs, Andrea Caballero, Josep Gregori, David Tabernero, Josep Quer, Leonardo Nieto, Rafael Esteban, Maria Buti, Francisco Rodriguez-Frias

    Published 2014-01-01
    Get full text
    Article
    Save to List
    Saved in:
  19. 19
    Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity

    Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity by Fernando Martínez-Valle, Mar Riveiro-Barciela, María-Teresa Salcedo, Xavier Merino-Casabiel, Andreu Fernández-Codina, Inés de Torres, Rafael Esteban, María Buti

    Published 2019-01-01
    Get full text
    Article
    Save to List
    Saved in:
  20. 20
    Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues?

    Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues? by Isabel Campos-Varela, Lluís Castells, María Buti, Víctor Vargas, Itxarone Bilbao, Francisco Rodríguez-Frías, Rosendo Jardí, Ramón Charco, Jaime Guardia, Rafael Esteban

    Published 2011-04-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: